Efficacy of adjuvant trastuzumab in women with HER2-positive T1a or bN0M0 breast cancer: a population-based cohort study
Shahid Ahmed(Emory University), Duc Le(University of Saskatchewan), KATE JOHNSON(Vancouver Coastal Health), Ali El‐Gayed, Haji Chalchal, Mehrnoosh Pauls(University of Saskatchewan), Philip Wright(University of Saskatchewan), Jace Hendry(University of Saskatchewan), Osama Ahmed(University of Saskatchewan), Kamal Haider(University of Saskatchewan), Amer Sami(University of Saskatchewan), Prosanta Mondal(Saskatchewan Health Authority)
Cited by 18
Related Papers
<i>K-ras</i> Mutations and Benefit from Cetuximab in Advanced Colorectal Cancer
|New England Journal of Medicine|2008|3.6k
Obesity and Cancer: A Current Overview of Epidemiology, Pathogenesis, Outcomes, and Management
|Cancers|2023|640
Gallbladder Cancer in the 21st Century
|Journal of Oncology|2015|301
Exemestane Versus Anastrozole in Postmenopausal Women With Early Breast Cancer: NCIC CTG MA.27—A Randomized Controlled Phase III Trial
|Journal of Clinical Oncology|2013|261
HER2-directed therapy: current treatment options for HER2-positive breast cancer
|Breast Cancer|2015|183